Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on PTC Therapeutics to $64 from $62 and keeps an Overweight rating on the shares following the revenue beat and raise. The firm says investors are not giving credit to PTC’s pipeline, where just one program working could lead to vast upside, the analyst says. The firm thinks there are two main pipeline drivers to move the stock, Sepiapterin in PKU and PTC518 in HD, with other opportunities representing pure upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Q2 Financial Performance and Updates Webinar
- PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Is PTCT a Buy, Before Earnings?
- PTC Therapeutics submits sepiapterin NDA to U.S. FDA
- Truist healthcare analyst holds an analyst/industry conference call